TABLE 3.
Association between the genetic risk score (GRS) of leukocyte telomere length and the mortality of 33 TCGA cancers.
| Cancer | HR (95%CI) | p | FDR | N | Median survival time |
M/F | Age at diagnosis (years) | Stage or grade (1/2/3/4/5) | ||
| All | Event | Censor | ||||||||
| DLBC | 2.24 (0.88–5.67) | 0.090 | 0.317 | 42 | 31.85 | 19.83 | 32.4 | 19/23 | 55.33 ± 14.39 | 8/17/5/12 |
| PCPG | 2.16 (0.95–4.92) | 0.068 | 0.283 | 178 | 25.28 | 15.08 | 25.6 | 78/100 | 47.30 ± 15.12 | NA |
| READ | 1.72 (1.09–2.73) | 0.020 | 0.138 | 157 | 21.2 | 24.33 | 21.02 | 85/72 | 64.34 ± 11.67 | 30/51/51/25 |
| UVM | 1.47 (0.94–2.30) | 0.092 | 0.320 | 79 | 25.77 | 19.68 | 27.37 | 44/35 | 61.68 ± 13.94 | 0/39/36/4 |
| PRAD | 1.44 (0.72–2.87) | 0.306 | 0.610 | 501 | 30.8 | 29.17 | 30.87 | 501/0 | 60.93 ± 6.81 | NA |
| SARC | 1.29 (1.06–1.58) | 0.011 | 0.138 | 260 | 31.77 | 21.6 | 36.4 | 119/141 | 60.80 ± 14.61 | NA |
| ESCA | 1.28 (0.99–1.66) | 0.063 | 0.274 | 162 | 13.57 | 13.38 | 13.57 | 137/25 | 62.40 ± 11.74 | 18/79/56/9 |
| TGCT | 1.23 (0.10–15.59) | 0.870 | 0.816 | 81 | 37.53 | 116.48 | 37.53 | 81/0 | 32.85 ± 10.18 | 55/12/14/0 |
| SKCM | 1.19 (1.03–1.37) | 0.018 | 0.138 | 411 | 33.2 | 31.93 | 34.5 | 256/155 | 58.82 ± 15.51 | 77/140/171/23 |
| KICH | 1.17 (0.46–2.99) | 0.743 | 0.792 | 65 | 74.93 | 28.5 | 90.43 | 38/27 | 51.15 ± 13.99 | 20/25/14/6 |
| CESC | 1.14 (0.90–1.45) | 0.274 | 0.583 | 295 | 21.27 | 20.23 | 23.12 | 0/295 | 47.88 ± 13.47 | 160/69/46/20 |
| THCA | 1.12 (0.66–1.89) | 0.676 | 0.776 | 503 | 31.67 | 34.03 | 31.47 | 136/367 | 47.28 ± 15.78 | 284/52/113/54 |
| BRCA | 1.11 (0.93–1.32) | 0.258 | 0.569 | 924 | 26.38 | 44.13 | 24.23 | 0/924 | 58.84 ± 13.14 | 156/523/219/14/12 |
| LUSC | 1.06 (0.93–1.21) | 0.378 | 0.659 | 487 | 21.77 | 18.13 | 24.58 | 359/128 | 67.31 ± 8.58 | 239/157/84/7 |
| MESO | 1.05 (0.82–1.35) | 0.705 | 0.783 | 86 | 17.1 | 15.23 | 38.93 | 70/16 | 63.08 ± 9.72 | 10/16/44/16 |
| LUAD | 1.04 (0.90–1.21) | 0.584 | 0.749 | 503 | 21.87 | 20.47 | 22.33 | 232/271 | 65.16 ± 10.07 | 277/121/80/25 |
| UCEC | 1.04 (0.84–1.28) | 0.742 | 0.791 | 546 | 30.47 | 23.63 | 32.2 | 0/546 | 63.99 ± 11.13 | 338/52/127/29 |
| KIRC | 1.04 (0.90–1.20) | 0.639 | 0.766 | 532 | 39.2 | 27.35 | 48.1 | 342/190 | 60.57 ± 12.07 | 267/57/125/83 |
| HNSC | 1.03 (0.90–1.19) | 0.655 | 0.770 | 450 | 21.37 | 14.08 | 27.4 | 324/126 | 60.90 ± 12.13 | 27/73/82/268 |
| LIHC | 1.00 (0.83–1.21) | 0.963 | 0.831 | 350 | 19.43 | 13.67 | 21.47 | 239/111 | 59.03 ± 13.30 | 174/86/85/5 |
| GBM | 1.00 (0.91–1.10) | 0.949 | 0.829 | 595 | 12.27 | 12.7 | 8.67 | 364/231 | 57.87 ± 14.41 | NA |
| ACC | 0.99 (0.68–1.44) | 0.967 | 0.832 | 88 | 37.93 | 18.38 | 48.45 | 29/59 | 47.07 ± 16.43 | 9/43/18/18 |
| OV | 0.98 (0.88–1.08) | 0.629 | 0.763 | 569 | 33.57 | 35.77 | 28.57 | 0/569 | 59.71 ± 11.46 | 16/30/437/86 |
| PAAD | 0.97 (0.80–1.19) | 0.792 | 0.802 | 182 | 15.55 | 13.13 | 16.92 | 100/82 | 64.92 ± 11.06 | 21/152/4/5 |
| STAD | 0.96 (0.83–1.11) | 0.576 | 0.746 | 407 | 14.53 | 11.6 | 18.87 | 260/147 | 65.37 ± 10.70 | 55/128/181/43 |
| BLCA | 0.96 (0.82–1.12) | 0.576 | 0.746 | 411 | 17.87 | 13.68 | 21.27 | 303/108 | 68.10 ± 10.58 | 3/131/141/136 |
| COAD | 0.93 (0.76–1.13) | 0.448 | 0.696 | 458 | 22.32 | 13.47 | 24.33 | 239/219 | 67.03 ± 13.06 | 79/183/131/65 |
| LGG | 0.89 (0.73–1.09) | 0.270 | 0.580 | 512 | 22.47 | 27.13 | 20.97 | 284/228 | 42.99 ± 13.34 | 0/247/265/0 |
| LAML | 0.89 (0.73–1.09) | 0.252 | 0.563 | 186 | 12.17 | 9.1 | 23.3 | 102/84 | 55.53 ± 16.06 | NA |
| UCS | 0.85 (0.59–1.23) | 0.395 | 0.669 | 56 | 20.25 | 16.72 | 27.6 | 0/56 | 69.38 ± 8.89 | 21/5/20/10 |
| THYM | 0.85 (0.41–1.76) | 0.654 | 0.770 | 121 | 41.77 | 28.43 | 42.33 | 62/59 | 58.37 ± 12.94 | 37/61/15/8 |
| KIRP | 0.66 (0.47–0.93) | 0.019 | 0.138 | 257 | 24.67 | 20.8 | 25.37 | 190/67 | 61.50 ± 12.03 | 171/20/51/15 |
| CHOL | 0.64 (0.38–1.08) | 0.097 | 0.331 | 36 | 21.5 | 16.67 | 31.42 | 16/20 | 63.03 ± 12.67 | 19/9/1/7 |
The cancers were sorted by the estimated hazard ratios (HRs). CI, confidence internal; p, the original p-value; FDR, false discovery rate; M, male; F, female. Cancer types: DLBC, lymphoid neoplasm diffuse large B-cell lymphoma; PCPG, pheochromocytoma and paraganglioma; READ, rectum adenocarcinoma; UVM, uveal melanoma; PRAD, prostate adenocarcinoma; SARC, sarcoma; ESCA, esophageal carcinoma; TGCT, testicular germ cell tumor; SKCM, skin cutaneous melanoma; KICH, kidney chromophobe; CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma; THCA, thyroid carcinoma; BRCA, breast invasive carcinoma; LUSC, lung squamous cell carcinoma; MESO, mesothelioma; LUAD, lung adenocarcinoma; UCEC, uterine corpus endometrial carcinoma; KIRC, kidney renal clear cell carcinoma; HNSC, head and neck squamous cell carcinoma; LIHC, liver hepatocellular carcinoma; GBM, glioblastoma multiforme; ACC, adrenocortical carcinoma; OV, ovarian serous cystadenocarcinoma; PAAD, pancreatic adenocarcinoma; STAD, stomach adenocarcinoma; BLCA, bladder urothelial carcinoma; COAD, colon adenocarcinoma; LGG, brain lower grade glioma; LAML, acute myeloid leukemia; UCS, uterine carcinosarcoma; THYM, thymoma; KIRP, kidney renal papillary cell carcinoma; CHOL, cholangiocarcinoma. In bold are suggestive associations (i.e., p < 0.05).